

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 31/575 // (A61K 31/575, 31:195) (A61K 31/575, 31:19)	A1	(11) International Publication Number: WO 97/34608 (43) International Publication Date: 25 September 1997 (25.09.97)
(21) International Application Number: PCT/US97/04615 (22) International Filing Date: 21 March 1997 (21.03.97) (30) Priority Data: 08/621,781 22 March 1996 (22.03.96) US 08/717,556 23 September 1996 (23.09.96) US (71) Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH [US/US]; 200 First Street S.W., Rochester, MN 55905 (US). (72) Inventors: LARSON, Mark, V.; 6700 80th Avenue N.E., Elgin, MN 55932 (US). AHLQUIST, David, A.; 6567 Buckridge Court N.E., Rochester, MN 55906 (US). PEARSON, Randall, K.; 2009 11th Street S.W., Rochester, MN 55902 (US). (74) Agent: VIKSNINS, Ann, S.; Schwegman, Lundberg, Woessner & Kluth, P.O. Box 2938, Minneapolis, MN 55402 (US).		(81) Designated States: AU, CA, JP, KR, MX, NZ, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: COMBINATIONS OF AN URSODEOXYCHOLIC ACID COMPOUND AND A NSAID FOR THE CHEMOPREVENTIVE PROTECTION OF THE COLORECTUM (57) Abstract <p>A method for protecting a colorectum against a recurrence of adenomas is provided, wherein ursodeoxycholic acid or an amide-conjugate thereof, or ursodeoxycholic acid or an amide-conjugate thereof in combination with sulindac or a phenolic NSAID is administered to a patient afflicted with colorectal adenomas in an amount effective to prevent the recurrence of colorectal adenomas following the removal thereof.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

COMBINATIONS OF AN URSODEOXYCHOLIC ACID COMPOUND AND A NSAID FOR THE CHEMOPREVENTIF PROTECTION OF THE COLORECTUM

5

Background of the Invention

Colorectal cancer is the most common visceral cancer in the United States. Each year, more than 160,000 new cases of colorectal cancer are detected which account for more than 60,000 deaths. The national incidence of colorectal cancer appears to be on the rise, as it increased by 9.4% from 1973 to 1986 based on a sample of 10% of the U.S. population. Unfortunately, the five-year survival rate has not improved significantly over the past four decades. As prognosis worsens with more advanced cancers, many physicians and several national medical societies advocate routine screening to increase early stage detection. However, while the rationale for screening is sound, such efforts at secondary prevention require an enormous use of medical resources and have not been shown to be effective in a general population.

Colorectal cancer provides unique opportunities for primary intervention among human malignancies because it progresses through clinically recognizable stages from normal mucosa through enlarging and increasingly dysplastic polyps which eventuate in carcinoma. Support for the adenoma to carcinoma sequence is provided by epidemiological studies, shared genetic properties of both adenomas and carcinomas, and the natural history of adenomas as observed in patients with familial adenomatous polyposis.

25 Nicholson ML, et al., "Increased Cell Membrane Arachidonic Acid in Experimental Colorectal Tumors," *Gut* 32:413-8 (1991); Fearon ER, et al., "Colonal Analysis of Human Colorectal Tumors," 238 Science 193 (1987); and Bussey HJR, "Familial Polyposis Coli," Family Studies, Histopathology, Differential Diagnosis, and Results of Treatment (Johns Hopkins University Press, Baltimore 1975). Genetic factors appear to mediate the development of colonic adenomas in familial adenomatous polyposis (FAP), for example, and may also play a role in the development of sporadic adenomas and carcinomas. In addition, there is evidence for an accumulating series of genetic deletions and

mutations including known oncogenes and tumor suppressors, that accompany the transition from normal mucosa to adenoma to carcinoma.

The precursor relationship of colorectal adenoma to carcinoma and the high prevalence of adenomas makes them an attractive target in chemoprevention trials. The prevalence increases with age in moderate and high risk populations, reaching 20-40% at the age of 50-60 years, and 50% or more for individuals older than 70 years. The steepest increase in adenoma prevalence occurs between the ages of 50-59. However, removal of polyps does not change the pathogenetic milieu responsible for their growth and development. The recurrence rate for colorectal adenomas has been variably reported, but most studies document an adenoma recurrence rate of 20-60% by two years. Nava H, et al., "Follow-up Colonoscopy in Patients With Colorectal Adenomatous Polyps," 30 Dis. Colon Rectum 465 (1987); Olsen HW, et al., "Review of Recurrent Polyps in Cancer in 500 Patients With Initial Colonoscopy for Polyps," 31 Dis. Colon Rectum 222 (1988); Williams CB and Macrae FA, "The St. Mark's Neoplastic Polyp Follow-up Study," 10 Front. Gastrointest. Res. 1226 (1986). Winawer recently reported that 28% of patients who had newly diagnosed adenomas removed by colonoscopy had additional polyps detected at a one-year follow-up examination, and of those patients, 22% had new adenomatous polyps again detected on examination two years later. Winawer SJ, et al., "Randomized Comparison of Surveillance Intervals After Colonoscopic Removal of Newly Diagnosed Adenomatous Polyps," 328 New Engl. J. Med. 901 (1993). Patients who have undergone surgical resection of a primary colorectal cancer have also been shown to be at high risk of developing metachronous adenomas. Olsen HW, et al., "Review of Recurrent Polyps in Cancer in 500 Patients With Initial Colonoscopy for Polyps," 31 Dis. Colon Rectum 222 (1988).

Several studies have focused attention on bile acids as a potential mediator of the dietary influence on colorectal cancer risk. Hofmann AF, "Chemistry and Enterohepatic Circulation of Bile Acids," Hepatology 4S-14S (1984). Bile acids are important detergents for fat solubilization and digestion in

the proximal intestine. Specific transport processes in the apical domain of the terminal ileal enterocyte and basolateral domain of the hepatocyte account for the efficient conservation in the enterohepatic circulation. Only a small fraction of bile acids enter the colon; however, perturbations of the cycling rate of bile acids by diet (e.g., fat) or surgery (e.g., cholecystectomy) may increase the fecal bile acid load and perhaps account for the associated increased risk of colon cancer. Hill MJ, "Bile Flow and Colon Cancer," 238 Mutation Review 313 (1990). Studies linking perturbations in fecal bile acids with human colon cancer, however, have been inconsistent and controversial. The inconsistencies could stem from differences in the populations studied, patient selection, or methodologic artifacts in measuring fecal bile acid excretion.

Thus, chemoprevention of colorectal cancer, by dietary or pharmacologic intervention, remains to be established. There is a continuing need, therefore, to develop new chemopreventative treatments for colorectal adenomas.

Summary of the Invention

The present invention provides a method for preventing a recurrence of colorectal adenomas in a human patient afflicted with such adenomas comprising administering ursodeoxycholic acid (URSO), or an amino acid conjugate of ursodeoxycholic acid or a pharmaceutically-acceptable salt thereof, in an amount effective to prevent the recurrence of colorectal adenomas following removal thereof. A dose of about 50 to 7500 mg per day of ursodeoxycholic acid, its amide-conjugate or a pharmaceutically-acceptable salt thereof is preferably administered to the patient. More preferably, the dose is about 200 mg to 5000 mg. For example, in the working examples presented herein below, the dose is at about 750 mg to 1500 mg per day. The ursodeoxycholic acid, its amide-conjugate or a pharmaceutically-acceptable salt thereof is preferably administered orally. If an amino acid conjugate of ursodeoxycholic acid is to be administered, it is preferred that the URSO be conjugated to taurine or glycine. More preferably, the URSO will be conjugated via an amido group to taurine.

Ursodeoxycholic acid is also referred to herein as "URSO" or "ursodiol" or "ursodeoxycholate." The taurine-conjugate of ursodeoxycholic acid is also referred to herein as "tauroursodeoxycholic acid" or "TURSO" or "tauroursodiol" or "taurodeoxycholate."

5 The present method optionally further comprises administering a nonsteroidal anti-inflammatory agent (NSAID), or a pharmaceutically-acceptable salt thereof, in combination with the administration of ursodeoxycholic acid, its amino acid conjugate or a pharmaceutically-acceptable salt thereof to prevent the recurrence of colorectal adenomas. Preferably, the nonsteroidal anti-
10 inflammatory agent is sulindac, a phenolic NSAID or a pharmaceutically acceptable salt thereof.

For example, if sulindac is selected as the NSAID, it can be administered orally at a dose of about 10 mg to 1500 mg per day. Preferably, sulindac is administered at a dose of about 50 mg to 500 mg per day. More
15 preferably the sulindac is orally administered at a dose of about 150 mg to 300 mg per day.

Phenolic NSAIDs useful in the present method include 5-aminosalicylic acid, acetylsalicylic acid, acetaminophen, sulfasalazine, benzalazine, olsalazine, N-acetyl-5-aminosalicylic acid, 4-amino-2-hydroxy
20 benzoic acid, or biologically equivalent metabolites thereof. Most preferably, the aminosalicylic acid is 5-aminosalicylic acid. 5-aminosalicylic acid is also referred to herein as 5-amino-2-hydroxy benzoic acid or mesalamine.

If mesalamine is selected for use in the present method, it can be administered orally at a dose of about 10 mg to 10000 mg per day. Preferably,
25 mesalamine is administered at a dose of about 500 mg to 8000 mg per day. More preferably the mesalamine is orally administered at a dose of about 1000 mg to 5000 mg per day.

As used herein with respect to the present method, the term "afflicted with" encompasses a patient at risk of recurrence or development of
30 colorectal adenomas, as well as a patient who has developed said adenomas, and who is at risk for recurrence or progression of the condition.

Detailed Description of the Invention

Ursodeoxycholate (URSO), which is the hydrophilic 7-beta epimer of chenodeoxycholate, is notable for its lack of cytotoxicity in a variety of model cell systems including colonic epithelia. As a drug, it is rapidly absorbed from the proximal small intestine, extracted by the liver, conjugated and secreted, whereupon it enters the enterohepatic circulation. These properties have led to its clinical use in gallstone dissolution and as proposed treatment in the chronic cholestatic cholangiopathies, primary biliary cirrhosis and sclerosing cholangitis.

URSO has the advantage of being virtually free of side effects. Doses of ursodeoxycholate at 15 mg/kg/day used in primary biliary cirrhosis trials were extremely well tolerated and without toxicity. Poupon RE, et al., "A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis," 324 New Engl. J. Med. 1548 (1991). An extensive review of the use of URSO in clinical trials revealed that treatment with URSO resulted in 1) an infrequent, transient elevation of hepatic transaminases, 2) a frequent reduction in serum triglycerides, and 3) a transient, mild diarrhea in 3% of patients (range = 0-9% of patients) that resolved spontaneously without dose reduction. Bachrach WH and Hofmann AF, "Ursodeoxycholic Acid in the Treatment of Cholesterol Cholelithiasis," 27 Dig. Dis. Sci. 833 (1982). Doses of up to 22-25 mg/kg/day can be well-tolerated. Further, the drug can be administered in a single daily dose, which can lead to improved compliance over multiple divided doses.

While the precise mechanism of action is unknown, the beneficial effect of URSO therapy is closely linked to the enrichment of the hepatic bile acid pool with this hydrophilic bile acid. It has thus been hypothesized that bile acids more hydrophilic than URSO will have even greater beneficial effects than URSO. For example, tauroursodeoxycholate (TURSO) the taurine conjugate of ursodeoxycholate.

In this respect, amino acid conjugates of URSO are significantly more polar than URSO. It has been shown that orally administered unconjugated

URSO undergoes rapid biotransformation to conjugated species during first pass clearance. Furthermore, it has been reported that negligible proportions of unconjugated URSO are present in the bile of humans. Therefore, the therapeutic effectiveness of URSO can be enhanced via conjugation. Crosignani
5 et al., "Tauroursodeoxycholic acid for the treatment of primary biliary cirrhosis: a dose-response study (abstract)", 18 Hepatology 606 (1993).

TURSO retains the positive characteristics of URSO administration including tolerance and low toxicity. In addition, compared with URSO, TURSO causes a greater increase in the hydrophilic/hydrophobic bile
10 acid pool, limits lithocholate formation and increases the hepatic URSO concentration. Rodrigues, C. et. al., "Tauroursodeoxycholate Increases Rat Liver Ursodeoxycholate Levels and Limits Lithocholate Formation Better Than Ursodeoxycholate," 109 Gastroenterology 564 (1995). Clinical trials using
15 TURSO suggest that, like URSO, TURSO is valuable as a drug to treat primary biliary cirrhosis. Ferri F. et al., "Taurodeoxycholic acid in the treatment of primary biliary cirrhosis. A controlled study in comparison to ursodeoxycholic acid," 143 Clinica Terapeutica 321 (1993).

Nonsteroidal anti-inflammatory drugs (NSAIDs), such as sulindac or phenolic NSAIDs can inhibit the neoplastic transformation of colorectal
20 epithelium. Several mechanisms may explain the NSAID chemopreventative effect; including inhibition of prostaglandin synthesis, growth factors, or genetic mutations that ultimately lead to colorectal cancer. As of yet, however, the exact mechanism(s) remains to be established.

All NSAIDs inhibit cyclooxygenase, the enzyme that converts
25 arachidonic acid to prostaglandins and thromboxanes. Patients receiving relatively low doses of NSAIDs (e.g., piroxicam, 7.5 mg/day) have shown a sustained, significant reduction (>20%) in colorectal mucosal PGE₂ concentrations. Earnest DL, et al., "NSAIDs for Prevention of Colon Cancer; Early Studies with Piroxicam in Humans," Presented at Fourth International
30 Conference on Prevention of Human Cancer: Nutrition in Chemoprevention Controversies (June 3-6, 1992). Immune surveillance is also enhanced by drugs

such as NSAIDs that reduce PGE₂ synthesis. *Id.* Thus, prostaglandin inhibition can potentially suppress abnormal proliferation of colorectal epithelium and progression toward dysplastic lesions.

Indomethacin, piroxicam, and sulindac have all been shown to
5 inhibit carcinogen-induced colonic tumors in rodents. Narisewa T, et al.,
"Inhibition of Development of Methylnitrosourea-Induced Rat Colon Tumors by
Indomethacin Treatment," 41 Cancer Research 1954 (1981); Pollard M, et al.,
"The Suppressive Effect of Paroxican on Autochthonous Intestinal Tumors in the
Rat," 21 Cancer Letters 57 (1983); Moorghen M, et al. "The Protective Effect of
10 Sulindac Against Chemically-Induced Primary Colonic Tumors in Mice," 156 J.
Pathol. 341 (1988). In humans, however, indomethacin achieves relatively low
colonic concentrations, and has not been shown to inhibit or induce regression of
colonic polyps. Hucher HB, et al., "Studies on the Absorption, Distribution, and
Excretion of Indomethacin in Various Species," 153 J. Pharmacol. Exp. Ther.
15 237 (1966).

The most dramatic example of abnormal colonic proliferation
occurs in familial adenomatous polyposis (FAP), a relatively rare genetic
disorder that manifests an extraordinary number of adenomatous colonic polyps
and resulting cancers in affected individuals. Since 1983, numerous published
20 reports have described moderate to marked polyp regression in FAP patients
treated with sulindac for up to six months. Waddell WR and Longhry RW,
"Sulindac for Polyposis of the Colon," 24 J. Surg. Onc. 83 (1983); Labayle D, et
al., "Sulindac Causes Regression of Rectal Polyps in Familial Adenomatous
Polyposis," 101 Gastroenterology 635 (1991); Rigau J, et al., "Effects of Long-
25 Term Sulindac Therapy on Colonic Polyposis" 115 Annals of Internal Medicine
952 (1991); Waddell WR, et al., "Sulindac for Polyposis of the Colon," 157 Am.
J. Surg. 175 (1989). This effect occurred both in patients with only residual
rectal mucosa (following total colectomy) and in patients with diffuse colonic
polyposis. Polyp regression was typically rapid. Polyps, however, recurred
30 relatively quickly after stopping sulindac.

On the other hand, although the mode of action is unclear, the ability of phenolic NSAIDs to scavenge radicals is thought to be a major factor responsible for the observed therapeutic efficacy. Fischer C., et. al., "Radical-derived Oxidation Products of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic Acid", 661 J. Chromatography, 57 (1994). It has further been hypothesized that production of reactive oxygen metabolites contribute significantly to the tissue injury that occurs during active inflammatory bowel disease. Ahnfelt-Rhonne I., et al., 38 Dan. Med. Bulletin, 291 (1991). Therefore, agents that decrease the amounts of reactive oxygen metabolites by inhibiting the production or scavenging may reduce the inflammatory reaction. Ahnfelt-Rhonne I., supra.

Mesalamine, which is the active metabolite of sulfasalazine, is a radical scavenger and its therapeutic action may be explained in-part through this effect. Ahnfelt-Rhonne I., et al., "Clinical Evidence Supporting the Radical Scavenger Mechanism of 5-aminosalicylic acid", 98 Gastroenterology 1162 (1990). In fact, it has been suggested that mesalamine may be useful as an anticarcinogenic compound. Mestecky J, "Antioxidant Properties of 5-aminosalicylic Acid: Potential Mechanism for its Protective Effect in Ulcerative Colitis," Advances in Mucosal Immunology, 1317-21 (Plenum Press, New York and London) (1995).

The potential chemopreventative benefits of sulindac, mesalamine or any other NSAID used as a single agent is tempered by their well-known toxicities and moderately high risk of intolerance. Abdominal pain, dyspepsia, nausea, diarrhea, constipation, rash, dizziness, or headache have been reported in 3-9% of patients. Physician's Desk Reference, 1433-1435 (Medical Economics Company, 1993). Toxicities reported in 1-3% of patients include flatulence, anorexia, gastrointestinal cramps, pruritus, nervousness, tinnitus, and edema. A large number of other toxicities have been reported associated with sulindac in less than 1% of cases, including renal and hepatic toxicity, and gastrointestinal bleeding. NSAIDs have been increasingly recognized as an important cause of peptic ulceration. The elderly appear to be especially vulnerable, as the

incidence of NSAID-induced gastroduodenal ulcer disease, including gastrointestinal bleeding, is higher in those over age 60; this is also the age group most likely to develop colorectal cancer, and therefore, most likely to benefit from chemoprevention.

5 The amount of URSO, TURSO, sulindac, or mesalamine required for use in treatment varies not only with the particular form of each agent but also with the severity of the symptoms being treated and the age and condition of the patient.

 For human dosage, effective amounts of URSO or amino acid
10 conjugated URSO would fall generally in the range of 50 to 7500 mg per day of ursodeoxycholic acid for adult patients. Preferably, the dose is about 200 mg to 5000 mg of URSO or amide-conjugated URSO per day. More preferably, the dose is about 750 mg to 1500 mg URSO or amide-conjugated URSO per day.

 Effective amounts of sulindac can be administered at a dose of
15 about 10 mg to 1500 mg per day. Preferably, sulindac is administered at a dose of about 50 mg to 500 mg per day. More preferably the sulindac is administered at a dose of about 150 mg to 300 mg per day. Compositions of this invention may be administered one or more times daily.

 Effective amounts of mesalamine can be administered at a dose of
20 about 10 mg to 10000 mg per day. Preferably, mesalamine is administered at a dose of about 500 mg to 8000 mg per day. More preferably the mesalamine is administered at a dose of about 1000 mg to 5000 mg per day.

 The pharmaceutically acceptable salts of the biologically active compounds may include carboxylic acid salts, such as alkali metal carboxylates
25 and quaternary ammonium salts. These physiologically acceptable salts are prepared by methods known in the art, e.g., by dissolving the free amine bases with an excess of the acid in aqueous alcohol, or neutralizing a free carboxylic acid with an alkali metal base such as a hydroxide, or with an amine.

 Although the compounds of the present invention and/or its salts
30 may be administered as the pure chemicals, it is preferable to present the active ingredient as a pharmaceutical composition. Pharmaceutical compositions

comprising unit dosage forms of URSO, TURSO, sulindac, mesalamine or salts thereof in combination with a pharmaceutically acceptable carrier are commercially available or may be prepared from standard ingredients using standard techniques. The invention thus further provides a pharmaceutical composition comprising one or more of the claimed compounds and/or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable carriers therefor and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof.

Pharmaceutical compositions include those suitable for oral or parenteral (including intramuscular, subcutaneous and intravenous) administration. The compositions may, where appropriate, be conveniently presented in discrete unit dosage forms and may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the active compound with liquid carriers, solid matrices, semi-solid carriers, finely divided solid carriers or combination thereof, and then, if necessary, shaping the product into the desired delivery system.

Pharmaceutical compositions suitable for oral administration may be presented as discrete unit dosage forms such as hard or soft gelatin capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or as granules; as a solution, a suspension or as an emulsion. The active ingredient may also be presented as a bolus, electuary or paste. Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents. The tablets may be coated according to methods well known in the art, i.e., with enteric coatings.

Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as

suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), or preservative.

The typical acceptable pharmaceutical carriers for use in oral formulations are exemplified by sugars as lactose, sucrose, mannitol, and sorbitol; starches such as corn starch, tapioca starch, and potato starch; cellulose and derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, and methyl cellulose; calcium phosphates such as dicalcium phosphate and tricalcium phosphate; sodium sulfate, calcium sulfate; polyvinyl pyrrolidone, polyvinyl alcohol, stearic acid, alkaline earth metal stearates such as magnesium stearate and calcium stearate; vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, and corn oil; nonionic, cationic and anionic surfactants; ethylene glycol polymers; beta-cyclodextrin; fatty alcohols and hydrolyzed cereal solids; as well as other non-toxic compatible fillers, binders, disintegrants, buffers, antioxidants, lubricants, flavoring agents, and the like commonly used in pharmaceutical formulations.

The compounds according to the invention may also be formulated for parenteral administration (e.g., by injection, for example, bolus injection or continuous infusion) and may be presented in unit dose form in ampules, pre-filled syringes, small bolus infusion containers or in multi-doses containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Injectable formulations use aqueous physiologically acceptable carriers, e.g., distilled water, and preferably contain a compatible buffer system selected to maintain the pH in the desired range of 6.5 to 8, preferably about 7.0 to 7.4. A typical buffer system is a combination of sodium dibasic phosphate and sodium monobasic phosphate. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use.

For topical administration to the epidermis, the compounds of the present invention may be formulated as ointments, creams or lotions, or as the active ingredient of a transdermal patch. Suitable transdermal delivery systems are disclosed, for example, in Fisher et al. (U.S. Patent Nos. 4,788,603) or Bawas et al. (U.S. Patent Nos. 4,931,279, 4,668,504 and 4,713,224) or Chien et al. (U.S. Patent Nos. 4,818,540, 5,296,230, and 5,045,319). When desired, the above-described compositions can be adapted to provide sustained or prolonged release of the active ingredient employed, e.g., by combination thereof with certain hydrophilic polymer matrices, e.g., comprising natural gels, synthetic polymer gels or mixtures thereof.

Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents, such as gelatin, vegetable oils, polyalkylene glycol, or alcohol. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents. The active ingredient can also be delivered via iontophoresis, e.g., as disclosed in U.S. Patent Nos. 4,140,122, 4,383,529, or 4,051,842. Topical compositions may also include standard liquid formulations, e.g., distilled water or physiological saline solutions, in combination with nontoxic thickeners and preservatives.

Compositions suitable for topical administration in the mouth include unit dosage forms such as lozenges comprising active ingredient in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; mucoadherent gels, and mouthwashes comprising the active ingredient in a suitable liquid carrier.

The pharmaceutical compositions according to the invention may also contain other adjuvants such as flavorings, coloring, antimicrobial agents, or preservatives.

It will be further appreciated that the amount of the compound, or an active salt or derivative thereof, required for use in treatment will vary not

only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.

The desired dose may conveniently be presented in a single dose
5 or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator.

The following examples are intended to illustrate but not limit the
10 invention.

EXAMPLE 1

A total of 900 patients are recruited to study the chemopreventative effects of ursodeoxycholic acid (URSO) to prevent the recurrence of metachronous adenomatous colorectal polyps. The study patients
15 are male and female, age 50 and older who have had complete endoscopic or surgical resection of a histologically verified colorectal adenoma (at least 5 mm in size) or early-stage carcinoma (Duke's A or B1) resulting in a neoplasm-free colorectum, within three months prior to entering the study. The study patients must have an intact rectum and more than half of the colorectum remaining.

20 The patients are divided into three treatment groups. The treatment groups, defined by the dosages of sulindac and URSO, are shown below:

Placebo	750 mg q/d URSO	750 mg b.i.d. URSO
n = 300	n = 300	n = 300

25

To ensure that both the patient and the medical professionals who care for the patient are blind to the identity of the treatment assignment, only the study coordinator and the study group statisticians have access to the uncoded list of patients' identification numbers and their treatment assignments. In
30 addition, all patients take the same number of pills each day (active drug, placebo or both). Patients take the URSO tablets (250 mg) or its placebo orally

twice a day with meals for about one year. URSO and placebo are available from Axcan Pharma (Interfalk, Canada Inc., Quebec, Canada).

One year after initiating the study, each patient receives a follow-up coloscopic examination. Following sedation with intravenous midazolam and/or a narcotic at doses deemed appropriate by the colonoscopist, the rectum is intubated and the colonoscope advanced to the cecum in the usual fashion. Upon withdrawal of the colonoscope, all neoplastic lesions are identified, and their location and size recorded. All neoplastic lesions visualized are removed in the usual fashion, using the electrocautery snare or hot biopsy-forceps technique.

5 and/or a narcotic at doses deemed appropriate by the colonoscopist, the rectum is intubated and the colonoscope advanced to the cecum in the usual fashion. Upon withdrawal of the colonoscope, all neoplastic lesions are identified, and their location and size recorded. All neoplastic lesions visualized are removed in the usual fashion, using the electrocautery snare or hot biopsy-forceps technique.

10 The colonoscopist documents (1) whether a complete or a limited examination was performed, (2) the quality of the preparation, and (3) whether or not all visualized polypoid tissue was removed.

The primary endpoint of the study is the recurrence of polyps considered as a dichotomous outcome. A logistic regression for polyp recurrence (yes/no) at one year is used to assess treatment effects. Distributions of polyp size and number is determined for and compared among randomized groups. Although the randomization procedure should result in balanced treatment groups, the stratification factors and a few other variables (e.g., size, number of index polyps) thought to be associated with recurrence of polyps are included as covariates in the logistic regression model. Patients who "drop out" during the follow-up period (either due to toxicity or non-compliance) are considered as treatment failures (recurrent polyps), based on an "intent to treat" philosophy. The incidence of toxicity and compliance rates for each treatment arm is estimated, and the rates are compared among the treatment groups using a logistic regression analysis.

15 recurrence (yes/no) at one year is used to assess treatment effects. Distributions of polyp size and number is determined for and compared among randomized groups. Although the randomization procedure should result in balanced treatment groups, the stratification factors and a few other variables (e.g., size, number of index polyps) thought to be associated with recurrence of polyps are

20 included as covariates in the logistic regression model. Patients who "drop out" during the follow-up period (either due to toxicity or non-compliance) are considered as treatment failures (recurrent polyps), based on an "intent to treat" philosophy. The incidence of toxicity and compliance rates for each treatment arm is estimated, and the rates are compared among the treatment groups using a

25 logistic regression analysis.

Summaries of the distribution of primary and secondary outcomes done by each stratification factor separately, is tabulated using means and standard errors, medians, and inter-quartile range, or percentages, as appropriate for continuous or discrete data. Distributions of primary and secondary endpoints is also tabulated separately by sex and by ethnic/racial minority status.

30 endpoints is also tabulated separately by sex and by ethnic/racial minority status.

EXAMPLE 2

A total of 1200 patients are recruited to study the chemopreventative effects of ursodeoxycholic acid (URSO), the nonsteroidal anti-inflammatory drug (NSAID) sulindac, or URSO in combination with sulindac, to prevent the recurrence of metachronous adenomatous colorectal polyps. The study patients are male and female, age 50 and older who have had complete endoscopic or surgical resection of a histologically verified colorectal adenoma (at least 5 mm in size) or early-stage carcinoma (Duke's A or B1) resulting in a neoplasm-free colorectum, within three months prior to entering the study. The study patients must have an intact rectum and more than half of the colorectum remaining.

The patients are divided into nine treatment groups. The treatment groups, defined by the dosages of sulindac and URSO, are shown below:

15		Placebo BID	750 mg qd URSO	750 mg BID URSO	TOTAL
	Placebo BID	n = 150	n = 100	n = 150	400
	150 mg qd Sulindac	n = 100	n = 200	n = 100	400
	150 mg BID Sulindac	n = 150	n = 100	n = 150	400
20	TOTAL	400	400	400	1200

The factorial design recruits 1200 total patients randomized as shown per cell, yielding 400 patients per dosage group for each study drug.

25 To ensure that both the patient and the medical professionals who care for the patient are blind to the identity of the treatment assignment, only the study coordinator and the study group statisticians have access to the uncoded list of patients' identification numbers and their treatment assignments. In addition, all patients take the same number of pills each day (active drug(s), placebo, or both). Patients take the sulindac tablets (150 mg) or its placebo

30

orally twice a day with meals for about one year. The URSO tablets (250 mg) or its placebo are also taken orally twice a day with meals for about one year.

Sulindac and its matching placebo are available from Merck Sharp and Dohme (West Point, PA). URSO and placebo are available from Interfalk (Quebec,

5 Canada).

One year after initiating the study, each patient receives a follow-up coloscopic examination. Following sedation with intravenous midazolam and/or a narcotic at doses deemed appropriate by the colonoscopist, the rectum is intubated and the colonoscope advanced to the cecum in the usual fashion. Upon
10 withdrawal of the colonoscope, all neoplastic lesions are identified, and their location and size recorded. All neoplastic lesions visualized are removed in the usual fashion, using the electrocautery snare or hot biopsy-forceps technique. The colonoscopist documents (1) whether a complete or a limited examination was performed, (2) the quality of the preparation, and (3) whether or not all
15 visualized polypoid tissue was removed.

The primary endpoint of the study is the recurrence of polyps considered as a dichotomous outcome. A logistic regression for polyp recurrence (yes/no) at one year is used to assess treatment effects. Distributions of polyp size and number is determined for and compared among randomized
20 groups. Although the randomization procedure should result in balanced treatment groups, the stratification factors and a few other variables (e.g., size, number of index polyps) thought to be associated with recurrence of polyps are included as covariates in the logistic regression model. Patients who "drop out" during the follow-up period (either due to toxicity or non-compliance) are
25 considered as treatment failures (recurrent polyps), based on an "intent to treat" philosophy. The incidence of toxicity and compliance rates for each treatment arm is estimated, and the rates are compared among the treatment groups using a logistic regression analysis.

Summaries of the distribution of primary and secondary outcomes
30 done by each stratification factor separately, is tabulated using means and standard errors, medians, and inter-quartile range, or percentages, as appropriate

for continuous or discrete data. Distributions of primary and secondary endpoints is also tabulated separately by sex and by ethnic/racial minority status.

NSAIDs are ubiquitous, are available in over-the-counter preparations as well as prescription varieties, and are often used to treat a wide spectrum of symptoms and diseases. In order to prevent contamination of groups by the inadvertent use of an NSAID, patients are given a list of NSAIDs, as well as a list of over-the-counter medications that contain an NSAID (e.g., Darvon contains aspirin). Patients are instructed to avoid these agents (Tylenol may be used). If the prolonged use of an NSAID is medically necessary, the patient is disqualified from the study.

EXAMPLE 3

A total of 1200 patients will be recruited to study the chemopreventative effects of tauroursodeoxycholic acid (TURSO), the phenolic NSAID mesalamine, or TURSO in combination with mesalamine, to prevent the recurrence of metachronous adenomatous colorectal polyps. The study patients will be male and female, age 50 and older who have had complete endoscopic or surgical resection of a histologically verified colorectal adenoma (at least 5 mm in size) or early-stage carcinoma (Duke's A or B1) resulting in a neoplasm-free colorectum, within three months prior to entering the study. The study patients must have an intact rectum and more than half of the colorectum remaining.

The patients will be divided into nine treatment groups. The treatment groups, defined by the dosages of mesalamine and TURSO, are shown below:

	Placebo BID	750 mg qd TURSO	750 mg BID TURSO	TOTAL
	n = 150	n = 100	n = 150	400
5	400 mg qd Mesalamine	n = 100	n = 200	400
	400 mg BID Mesalamine	n = 150	n = 100	400
	TOTAL	400	400	1200

- 10 The factorial design recruits 1200 total patients randomized as shown per cell, yielding 400 patients per dosage group for each study drug.

To ensure that both the patient and the medical professionals who care for the patient are blind to the identity of the treatment assignment, only the study coordinator and the study group statisticians will have access to the

15 uncoded list of patients' identification numbers and their treatment assignments. In addition, all patients will take the same number of pills each day (active drug(s), placebo, or both). Patients will take the mesalamine tablets (400 mg) or its placebo orally twice a day with meals for about one year. The TURSO tablets (750 mg) or its placebo will also be taken orally twice a day with meals for about

20 one year. Mesalamine and its matching placebo are available from Procter and Gamble Pharmaceuticals (Norwich, N.Y.). TURSO and placebo are available from Interfalk (Quebec, Canada).

One year after initiating the study, each patient will receive a follow-up coloscopic examination. Following sedation with intravenous

25 midazolam and/or a narcotic at doses deemed appropriate by the colonoscopist, the rectum will be intubated and the colonoscope advanced to the cecum in the usual fashion. Upon withdrawal of the colonoscope, all neoplastic lesions will be identified, and their location and size recorded. All neoplastic lesions visualized will be removed in the usual fashion, using the electrocautery snare or

30 hot biopsy-forceps technique. The colonoscopist will document (1) whether a

complete or a limited examination was performed, (2) the quality of the preparation, and (3) whether or not all visualized polypoid tissue was removed.

The primary endpoint of the study will be the recurrence of polyps considered as a dichotomous outcome. A logistic regression for polyp recurrence (yes/no) at one year will be used to assess treatment effects. Distributions of polyp size and number will be determined for and compared among randomized groups. Although the randomization procedure should result in balanced treatment groups, the stratification factors and a few other variables (e.g., size, number of index polyps) thought to be associated with recurrence of polyps will be included as covariates in the logistic regression model. Patients who "drop out" during the follow-up period (either due to toxicity or non-compliance) will be considered as treatment failures (recurrent polyps), based on an "intent to treat" philosophy. The incidence of toxicity and compliance rates for each treatment arm will be estimated, and the rates are compared among the treatment groups using a logistic regression analysis.

Summaries of the distribution of primary and secondary outcomes done by each stratification factor separately, will be tabulated using means and standard errors, medians, and inter-quartile range, or percentages, as appropriate for continuous or discrete data. Distributions of primary and secondary endpoints will also be tabulated separately by sex and by ethnic/racial minority status.

NSAIDs are ubiquitous, are available in over-the-counter preparations as well as prescription varieties, and are often used to treat a wide spectrum of symptoms and diseases. In order to prevent contamination of groups by the inadvertent use of an NSAID, patients will given a list of NSAIDs, as well as a list of over-the-counter medications that contain an NSAID (e.g., Darvon contains aspirin). Patients will be instructed to avoid these agents. If the prolonged use of an NSAID becomes medically necessary, the patient will be disqualified from the study.

The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be

understood that many variations and modifications may be made while remaining within the scope of the invention.

WHAT IS CLAIMED IS:

1. A use of a ursodeoxycholic acid compound, or a pharmaceutically-acceptable salt thereof, and a nonsteroidal anti-inflammatory agent for the preparation of a medicament for protecting the colorectum of a human patient against a recurrence of colorectal adenomas following the removal of colorectal adenomas.
2. The use of claim 1 wherein the medicament is formulated to comprise about 50 to 7500 mg of ursodeoxycholic acid.
3. The use of claim 1 wherein the nonsteroidal anti-inflammatory agent is sulindac.
4. The use of claim 3 wherein the medicament is formulated to comprise about 10 mg to 1500 mg of sulindac.
5. The use of claim 1 wherein the nonsteroidal anti-inflammatory agent is a phenolic nonsteroidal anti-inflammatory agent.
6. The use of claim 5 wherein the phenolic nonsteroidal anti-inflammatory agent is mesalamine.
7. A use of an amino acid conjugate of ursodeoxycholic acid, or a pharmaceutically-acceptable salt thereof, for the preparation of a medicament for protecting the colorectum of a human patient against a recurrence of colorectal adenomas following the removal of colorectal adenomas.
8. The use of claim 7 wherein the amino acid conjugate of ursodeoxycholic acid is tauroursodeoxycholic acid.

9. The use of claim 8 wherein the medicament comprises of 50 to 7500 mg of tauroursodeoxycholic acid.
10. A use of an amino acid conjugate of ursodeoxycholic acid, or a pharmaceutically-acceptable salt thereof, and a nonsteroidal anti-inflammatory agent for the preparation of a medicament for protecting the colorectum of a human patient against a recurrence of colorectal adenomas following the removal of colorectal adenomas.
11. The use of claim 10 wherein the nonsteroidal anti-inflammatory agent is sulindac or a phenolic nonsteroidal anti-inflammatory agent.
12. The use of claim 10 wherein the nonsteroidal anti-inflammatory agent comprises about 10 mg to 1500 mg sulindac.
13. The use of claim 11 wherein the phenolic nonsteroidal anti-inflammatory agent is mesalamine.
14. The use of claim 13 wherein the medicament comprises about 10 mg to 10,000 mg of mesalamine.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/04615

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/575 //(A61K31/575,31:195),(A61K31/575,31:19)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EUROPEAN JOURNAL OF CANCER, 31A (7-8). 1995. 1198-1204., XP002035381 SCHATZKIN A ET AL: "Chemo- and Dietary Prevention of Colorectal Cancer" see page 1200, column 2, paragraph 4 - page 1201, column 1, line 5 see page 1201, column 2, paragraph 6 - page 1202, column 1, paragraph 1 ---	1-14
A	WO 93 25192 A (CORTECS LTD ;BARNWELL STEPHEN GEORGE (GB)) 23 December 1993 see claims 1-7 -----	1-14

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

16 July 1997

Date of mailing of the international search report

31.07.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Leherte, C

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/04615

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9325192 A	23-12-93	AU 671285 B	22-08-96
		AU 4345693 A	04-01-94
		EP 0644757 A	29-03-95
		JP 7508724 T	28-09-95
		NZ 253262 A	25-06-96
